![](/images/general/no_picture/200_user.png)
Shanetta D Ore
Examiner (ID: 16151)
Most Active Art Unit | 2833 |
Art Unit(s) | 2833 |
Total Applications | 10 |
Issued Applications | 9 |
Pending Applications | 0 |
Abandoned Applications | 1 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16932786
[patent_doc_number] => 20210198675
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => METHODS OF TREATING CANCER AND/OR ENHANCING SENSITIVITY TO CANCER TREATMENT BY INCREASING TUMOR MUTATION BURDEN OR TUMOR INDELS
[patent_app_type] => utility
[patent_app_number] => 16/757583
[patent_app_country] => US
[patent_app_date] => 2018-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13879
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757583
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/757583 | METHODS OF TREATING CANCER AND/OR ENHANCING SENSITIVITY TO CANCER TREATMENT BY INCREASING TUMOR MUTATION BURDEN OR TUMOR INDELS | Oct 22, 2018 | Pending |
Array
(
[id] => 16916244
[patent_doc_number] => 20210189336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => BITE-ACTIVATED CAR-T CELLS
[patent_app_type] => utility
[patent_app_number] => 16/757522
[patent_app_country] => US
[patent_app_date] => 2018-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757522
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/757522 | BITE-ACTIVATED CAR-T CELLS | Oct 17, 2018 | Pending |
Array
(
[id] => 14273865
[patent_doc_number] => 20190134217
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS
[patent_app_type] => utility
[patent_app_number] => 16/158164
[patent_app_country] => US
[patent_app_date] => 2018-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158164
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/158164 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | Oct 10, 2018 | Abandoned |
Array
(
[id] => 14775047
[patent_doc_number] => 20190262421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => MODULATORS OF SYNDECAN-2 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/155732
[patent_app_country] => US
[patent_app_date] => 2018-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16155732
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/155732 | Modulators of syndecan-2 and uses thereof | Oct 8, 2018 | Issued |
Array
(
[id] => 16613624
[patent_doc_number] => 20210032277
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => PROGRAMMABLE POLYMERIC DRUGS
[patent_app_type] => utility
[patent_app_number] => 16/639496
[patent_app_country] => US
[patent_app_date] => 2018-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22139
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -50
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639496
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/639496 | PROGRAMMABLE POLYMERIC DRUGS | Oct 4, 2018 | Pending |
Array
(
[id] => 14156475
[patent_doc_number] => 20190105340
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMICRY
[patent_app_type] => utility
[patent_app_number] => 16/152080
[patent_app_country] => US
[patent_app_date] => 2018-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17687
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152080
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/152080 | METHODS AND COMPOSITIONS FOR TARGETING VASCULAR MIMICRY | Oct 3, 2018 | Abandoned |
Array
(
[id] => 13867467
[patent_doc_number] => 20190030074
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound
[patent_app_type] => utility
[patent_app_number] => 16/149468
[patent_app_country] => US
[patent_app_date] => 2018-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12745
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16149468
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/149468 | Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound | Oct 1, 2018 | Abandoned |
Array
(
[id] => 14158807
[patent_doc_number] => 20190106506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-11
[patent_title] => CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 16/140089
[patent_app_country] => US
[patent_app_date] => 2018-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38615
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16140089
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/140089 | CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER | Sep 23, 2018 | Abandoned |
Array
(
[id] => 16671395
[patent_doc_number] => 20210060158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/644159
[patent_app_country] => US
[patent_app_date] => 2018-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644159
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/644159 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | Sep 18, 2018 | Abandoned |
Array
(
[id] => 15163337
[patent_doc_number] => 10487149
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-26
[patent_title] => Nucleic acid-polypeptide compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/129694
[patent_app_country] => US
[patent_app_date] => 2018-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 136
[patent_figures_cnt] => 141
[patent_no_of_words] => 96080
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129694
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/129694 | Nucleic acid-polypeptide compositions and uses thereof | Sep 11, 2018 | Issued |
Array
(
[id] => 14040551
[patent_doc_number] => 20190076382
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-14
[patent_title] => Targeted Treatment Of Anerobic Cancer
[patent_app_type] => utility
[patent_app_number] => 16/129051
[patent_app_country] => US
[patent_app_date] => 2018-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129051
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/129051 | Targeted Treatment Of Anerobic Cancer | Sep 11, 2018 | Abandoned |
Array
(
[id] => 13733269
[patent_doc_number] => 20180371102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/128440
[patent_app_country] => US
[patent_app_date] => 2018-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 95768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128440
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/128440 | Nucleic acid-polypeptide compositions and uses thereof | Sep 10, 2018 | Issued |
Array
(
[id] => 17363592
[patent_doc_number] => 11230609
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-25
[patent_title] => Humanised anti kallikrein-2 antibody
[patent_app_type] => utility
[patent_app_number] => 16/117522
[patent_app_country] => US
[patent_app_date] => 2018-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 21
[patent_no_of_words] => 19089
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16117522
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/117522 | Humanised anti kallikrein-2 antibody | Aug 29, 2018 | Issued |
Array
(
[id] => 16468210
[patent_doc_number] => 20200369747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => METHODS OF INACTIVATING VIRAL CONTAMINANTS
[patent_app_type] => utility
[patent_app_number] => 16/641281
[patent_app_country] => US
[patent_app_date] => 2018-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641281
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/641281 | METHODS OF INACTIVATING VIRAL CONTAMINANTS | Aug 26, 2018 | Pending |
Array
(
[id] => 18133925
[patent_doc_number] => 11559574
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-24
[patent_title] => Whole-cell cancer vaccines and methods for selection thereof
[patent_app_type] => utility
[patent_app_number] => 16/110317
[patent_app_country] => US
[patent_app_date] => 2018-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 38
[patent_no_of_words] => 49673
[patent_no_of_claims] => 81
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16110317
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/110317 | Whole-cell cancer vaccines and methods for selection thereof | Aug 22, 2018 | Issued |
Array
(
[id] => 13625371
[patent_doc_number] => 20180364237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-20
[patent_title] => Monitoring Cancer Stem Cells
[patent_app_type] => utility
[patent_app_number] => 16/109122
[patent_app_country] => US
[patent_app_date] => 2018-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -49
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16109122
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/109122 | Monitoring Cancer Stem Cells | Aug 21, 2018 | Abandoned |
Array
(
[id] => 16612234
[patent_doc_number] => 20210030887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 16/975406
[patent_app_country] => US
[patent_app_date] => 2018-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975406
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/975406 | NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATE | Aug 17, 2018 | Pending |
Array
(
[id] => 18302074
[patent_doc_number] => 11623965
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-11
[patent_title] => Prodruggable antibodies, prodrugs thereof, and methods of use and making
[patent_app_type] => utility
[patent_app_number] => 16/103654
[patent_app_country] => US
[patent_app_date] => 2018-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 11673
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16103654
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/103654 | Prodruggable antibodies, prodrugs thereof, and methods of use and making | Aug 13, 2018 | Issued |
Array
(
[id] => 17267542
[patent_doc_number] => 11192954
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => Compounds and methods for the treatment of TROP2 positive diseases
[patent_app_type] => utility
[patent_app_number] => 16/100995
[patent_app_country] => US
[patent_app_date] => 2018-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 28
[patent_no_of_words] => 13704
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100995
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/100995 | Compounds and methods for the treatment of TROP2 positive diseases | Aug 9, 2018 | Issued |
Array
(
[id] => 13733243
[patent_doc_number] => 20180371089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-27
[patent_title] => ASYMMETRIC HETERODIMERIC FC-SCFV FUSION ANTI-GLOBO H AND ANTI-CD3 BISPECIFIC ANTIBODY AND USES THEREOF IN CANER THERAPY
[patent_app_type] => utility
[patent_app_number] => 16/016525
[patent_app_country] => US
[patent_app_date] => 2018-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6442
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016525
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/016525 | ASYMMETRIC HETERODIMERIC FC-SCFV FUSION ANTI-GLOBO H AND ANTI-CD3 BISPECIFIC ANTIBODY AND USES THEREOF IN CANER THERAPY | Jun 21, 2018 | Abandoned |